SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is gaining significant attention following its announcement of $10 million in new orders for autonomous systems, including counter-UAS and robotic ground solutions, signaling a strong demand in global defense and security. The community is buzzing with bullish sentiment, anticipating further growth as recent FCC actions against foreign drone imports create a compelling market opportunity for domestic manufacturers like Ondas, with many discussing a potential short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is actively trending following the FDA approval of NEREUS, marking the first new motion sickness treatment in over 40 years. The community is highly focused on NEREUS's potential to address GLP-1 induced nausea, seeing this as a massive market opportunity and positioning VNDA as a compelling buyout target for larger pharmaceutical companies. This significant regulatory win, alongside a strong pipeline, is driving optimism for substantial future upside.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending with high volatility, driven by its exceptionally low public float and significant insider ownership. The community is actively discussing its potential for a short squeeze, frequently drawing comparisons to other recent low-float SPACs that experienced rapid price surges. Sentiment remains bullish, fueled by speculation that its tight share structure could lead to further dramatic moves.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a surge in conversation after significant insider buying, including notable purchases by CEO Elliott Hill and Apple CEO Tim Cook, signaled strong confidence in the company's prospects. This has sparked widespread bullish sentiment about a potential turnaround and a possible short squeeze, though some remain cautious, highlighting ongoing market challenges and competition.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following the FDA's Complete Response Letter for its relacorilant drug, which cited a need for more efficacy evidence despite the GRACE trial meeting its primary endpoint. This news has sparked a polarized debate, with many investors viewing the substantial stock drop as an overreaction and a prime "bargain biobuy" given the company's strong existing revenue and extensive pipeline. However, others remain cautious, calling it a "total reset" while some attribute parts of the decline to typical end-of-year tax-loss selling.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as year-end tax loss selling and broader crypto market sentiment fuel a sharp divide among holders. The community actively debates whether current levels present a buying opportunity for a future rally or if further declines are imminent, reflecting a mix of long-term conviction and short-term volatility concerns.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is trending amidst significant market volatility following repeated increases in margin requirements by the CME Group for precious metal futures. This has sparked intense debate, with many asserting that these actions are an attempt to suppress price discovery and protect short positions against strong industrial demand and potential global supply shifts, while others view the recent rally as unsustainable. The community is sharply divided between those accumulating on dips, expecting a substantial long-term rise, and those predicting a significant correction.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is experiencing significant momentum following FDA updates, notably the acceptance with priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation. The community is highly optimistic, celebrating current gains and actively discussing the substantial long-term potential of its pipeline, especially as positive pre-NDA feedback was also received for AXS-12 in narcolepsy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below 50-Day Moving Average - Here's What Happened

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Fifty Day Moving Average - Here's Why...

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm...

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Recommendation of "Moderate Buy" from Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat.com reports. One...

ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Zacks Research

Zacks Research raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday...

ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts...

ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates

ProQR (PRQR) delivered earnings and revenue surprises of -20.00% and -60.57%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

Alkermes (ALKS) delivered earnings and revenue surprises of +16.67% and +10.83%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +3.88% and +9.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company was founded by Daniel Anton de Boer, Gerard J. Platenburg, Henri A. Termeer, and Domenico Valerio on February 21, 2012, and is headquartered in Leiden, the Netherlands.

PRQR
ProQR Therapeutics N.V

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRQR News

PRQRProQR Therapeutics N.V